The Effects of Periodontal Therapy on Gingival Crevicular Fluid NLRP3,Caspase-1,IL-1β Levels in Children With Gingivitis

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06507280

Enrollment

Registered

2024-07-18

Start date

2024-02-01

Completion date

2025-01-01

Last updated

2024-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingivitis

Keywords

NLRP3, CASPASE-1, IL-1β, GINGIVITIS, GCF

Brief summary

This study aims to determine the levels of NLRP3, caspase-1 and IL-1β concentrations in the gingival crevicular fluid of paediatric patients with gingivitis and their changes after periodontal treatment.

Detailed description

After being informed about the study and potential risks, necessary periodontal measurements will be performed and gingival crevicular fluid will be collected from all patients who gave written informed consent, and patients with gingivitis will be followed up on the 7th and 30th day after periodontal treatment.

Interventions

PROCEDUREPeriodontal theraphy

periodontal therapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

11 Years to 14 Years

Healthy volunteers

Yes

Inclusion criteria

Inclusion criteria for the group with gingivitis; * Systemically healthy * 11-14 years old * Permanent dentition * No need for endodontic and restorative treatment * Gingivitis with gingivitis * Have verbally and in writing agreed to participate in the study and are willing to attend follow-up appointments regularly participants will be included in the study. Inclusion criteria for the healthy group; * Systemically healthy * 11-14 years old * Permanent dentition * No need for endodontic and restorative treatment * Periodontally healthy * Have verbally and in writing agreed to participate in the study and are willing to attend follow-up appointments regularly participants will be included in the study.

Exclusion criteria

* In need of endodontic and restorative treatment * Systemically unhealthy * Patients who do not give verbal or written consent

Design outcomes

Primary

Measure	Time frame	Description
NLRP3	Baseline	NOD-, LRR- and pyrin domain-containing protein 3 level
Caspase-1	Baseline	Caspase-1 level
IL-1 Beta	Baseline	Interleukin-1 Beta level

Secondary

Measure	Time frame	Description
NLRP3	7. days - 30. days	NOD-, LRR- and pyrin domain-containing protein 3 level
Caspase-1	7. days -30. days	Caspase-1 level
IL-1 Beta	7. days-30. days	Interleukin-1 Beta level

Countries

Turkey (Türkiye)

Contacts

Primary ContactSultan Keleş, Assoc.Prof.

dtsultank@gmail.com05318438557

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026